14.13
前日終値:
$14.24
開ける:
$14.26
24時間の取引高:
194.34K
Relative Volume:
1.04
時価総額:
$957.56M
収益:
$-9,000
当期純損益:
$-68.03M
株価収益率:
-13.46
EPS:
-1.05
ネットキャッシュフロー:
$-44.76M
1週間 パフォーマンス:
+4.74%
1か月 パフォーマンス:
-1.87%
6か月 パフォーマンス:
-10.40%
1年 パフォーマンス:
-19.94%
Pulse Biosciences Inc Stock (PLSE) Company Profile
PLSE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
PLSE
Pulse Biosciences Inc
|
14.13 | 965.01M | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
559.52 | 192.25B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
200.09 | 57.34B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.19 | 38.71B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
253.07 | 36.82B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
WST
West Pharmaceutical Services Inc
|
271.86 | 19.25B | 2.96B | 487.70M | 344.00M | 6.6758 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-07 | 開始されました | Oppenheimer | Outperform |
| 2021-07-27 | 開始されました | Stephens | Overweight |
| 2021-03-11 | 開始されました | Maxim Group | Buy |
| 2021-01-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-12 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Pulse Biosciences Inc (PLSE) 最新ニュース
How (PLSE) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
Pulse Biosciences holds 2025 annual stockholder meeting - MSN
Pulse Biosciences (NASDAQ:PLSE) Trading Up 5%Here's What Happened - MarketBeat
Pulse Biosciences drops 38% after InvestingPro’s "Overvalued" warning By Investing.com - Investing.com Australia
Pulse Biosciences Holds 2025 Annual Stockholder Meeting - TipRanks
PLSE Starts Research Work on nPulse Technology to Treat Thyroid Tumor - sharewise.com
Pulse Biosciences and MD Anderson to study nPulse for thyroid cancer - Yahoo
Pulse Biosciences, Inc. Announces Research Collaboration with MD Anderson - TradingView — Track All Markets
Pulse Biosciences, MD Anderson, launch study of novel ablation technology for thyroid cancer - Medical Economics
Pulse Biosciences to evaluate PFA in treating thyroid cancer - MassDevice
Pulse Biosciences (PLSE) Collaborates with MD Anderson for Thyro - GuruFocus
Pulse Biosciences to begin thyroid cancer treatment study in 2026 - Investing.com
Pulse Biosciences to begin thyroid cancer treatment study in 2026 By Investing.com - Investing.com South Africa
Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology - Business Wire
With 73% ownership, insiders at Pulse Biosciences, Inc. (NASDAQ:PLSE) are pretty optimistic and have been buying recently - Yahoo Finance
Is Pulse Biosciences Inc. stock a buy before product launchesDollar Strength & AI Enhanced Trading Alerts - Newser
Bull Run: Is Pulse Biosciences Inc stock near bottom after declineJuly 2025 Retail & Stock Portfolio Risk Management - BỘ NỘI VỤ
How cyclical is Pulse Biosciences Inc. (6L8) stock compared to rivalsRecession Risk & Weekly High Return Forecasts - Newser
Is Pulse Biosciences Inc. stock a safe investment in uncertain markets2025 Institutional Moves & Real-Time Volume Analysis - Newser
Trading Systems Reacting to (PLSE) Volatility - news.stocktradersdaily.com
Is Pulse Biosciences Inc. stock a defensive play in 2025Trade Volume Report & Safe Entry Zone Identification - Newser
Is Pulse Biosciences Inc. stock near bottom after declineDay Trade & Reliable Breakout Stock Forecasts - Newser
Will Pulse Biosciences Inc. (6L8) stock benefit from Fed rate cutsVolume Spike & Community Trade Idea Sharing - Newser
PLSE: Nanosecond PFA enables disruptive, non-thermal ablation with rapid clinical and commercial expansion - TradingView — Track All Markets
How dovish Fed policy supports Pulse Biosciences Inc. (6L8) stockJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Pulse Biosciences (PLSE) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Will Pulse Biosciences Inc. (6L8) stock benefit from mergersJuly 2025 Selloffs & Consistent Income Trade Ideas - Newser
Value Recap: Can Pulse Biosciences Inc. stock beat market expectations this quarter - moha.gov.vn
Operating cash flow per share of Pulse Biosciences, Inc. – SWB:6L8 - TradingView
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 21, 2025 - BioSpace
How Pulse Biosciences Inc (PLSE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pulse Biosciences announces inducement grants under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Is Pulse Biosciences Inc. (6L8) stock in buy zone after pullbackJuly 2025 Sector Moves & Breakout Confirmation Alerts - newser.com
Is Pulse Biosciences Inc. stock supported by innovation pipelineJuly 2025 Reactions & Real-Time Stock Movement Alerts - newser.com
Will Pulse Biosciences Inc. stock maintain momentum in 20252025 Performance Recap & Real-Time Volume Analysis - newser.com
Top chart patterns to watch in Pulse Biosciences Inc.July 2025 Price Swings & High Conviction Trade Alerts - newser.com
How high can Pulse Biosciences Inc. stock goJuly 2025 Macro Moves & Weekly High Return Opportunities - newser.com
What recovery options are there for Pulse Biosciences Inc.Entry Point & Free AI Powered Buy and Sell Recommendations - newser.com
Can Pulse Biosciences Inc. (6L8) stock resist broad market declinesWatch List & Growth Focused Entry Point Reports - newser.com
Why hedge funds are buying Pulse Biosciences Inc. stockJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Will Pulse Biosciences Inc. (6L8) stock draw ESG focused fundsTrend Reversal & Daily Volume Surge Signals - newser.com
Why Pulse Biosciences Inc. (6L8) stock benefits from AI revolutionEarnings Risk Report & Risk Managed Investment Entry Signals - newser.com
Pulse Biosciences Inc (PLSE) 財務データ
収益
当期純利益
現金流量
EPS
Pulse Biosciences Inc (PLSE) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Oct 02 '25 |
Sale |
18.53 |
4,600 |
85,238 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Option Exercise |
1.53 |
400 |
612 |
43,698 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 18 '25 |
Sale |
18.49 |
20,000 |
369,800 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Sep 19 '25 |
Sale |
18.48 |
400 |
7,392 |
43,298 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Option Exercise |
4.00 |
181,534 |
726,136 |
284,406 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Option Exercise |
4.00 |
25,000 |
100,000 |
147,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 16 '25 |
Sale |
16.28 |
25,000 |
407,000 |
122,872 |
| UECKER DARRIN | Chief Technology Officer |
Sep 17 '25 |
Sale |
16.21 |
20,000 |
324,200 |
122,872 |
大文字化:
|
ボリューム (24 時間):